Abstract |
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.
|
Authors | E Rubinstein, S Cammarata, T Oliphant, R Wunderink, Linezolid Nosocomial Pneumonia Study Group |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 32
Issue 3
Pg. 402-12
(Feb 01 2001)
ISSN: 1058-4838 [Print] United States |
PMID | 11170948
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Acetamides
- Anti-Bacterial Agents
- Monobactams
- Oxazolidinones
- Vancomycin
- Aztreonam
- Linezolid
|
Topics |
- Acetamides
(adverse effects, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Aztreonam
(therapeutic use)
- Cross Infection
(drug therapy)
- Double-Blind Method
- Drug Resistance, Microbial
- Drug Therapy, Combination
- Gram-Positive Bacteria
(drug effects)
- Hospitalization
- Humans
- Linezolid
- Male
- Middle Aged
- Monobactams
(therapeutic use)
- Oxazolidinones
(adverse effects, therapeutic use)
- Pneumonia
(drug therapy)
- Safety
- Time Factors
- Treatment Outcome
- Vancomycin
(adverse effects, therapeutic use)
|